Cargando…
Gestational diabetes in Germany: Development of screening participation and prevalence
Gestational diabetes mellitus (GDM) is an important risk factor for pregnancy complications. Since 2012, the Federal Joint Committee’s maternity directive recommends a two-step screening for GDM with a pre-test and subsequent diagnostic test if the pre-test is positive. This study analyses the imple...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Robert Koch Institute
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734204/ https://www.ncbi.nlm.nih.gov/pubmed/35146306 http://dx.doi.org/10.25646/8325 |
_version_ | 1784627967767347200 |
---|---|
author | Reitzle, Lukas Schmidt, Christian Heidemann, Christin Icks, Andrea Kaltheuner, Matthias Ziese, Thomas Scheidt-Nave, Christa |
author_facet | Reitzle, Lukas Schmidt, Christian Heidemann, Christin Icks, Andrea Kaltheuner, Matthias Ziese, Thomas Scheidt-Nave, Christa |
author_sort | Reitzle, Lukas |
collection | PubMed |
description | Gestational diabetes mellitus (GDM) is an important risk factor for pregnancy complications. Since 2012, the Federal Joint Committee’s maternity directive recommends a two-step screening for GDM with a pre-test and subsequent diagnostic test if the pre-test is positive. This study analyses the implementation and development over time of GDM screening participation and prevalence in Germany. The data basis is the external inpatient obstetrics quality assurance documentation, which covers all births in hospital. Women with diabetes before pregnancy were excluded. The study defined women as GDM cases if the condition was documented in maternity records or if the ICD-10 diagnosis O24.4 was coded for inpatients at discharge and figures were determined for the years 2013 to 2018. As the documentation of screening tests has only been included in the data set since 2016, screening participation for the years 2016 to 2018 were estimated and evaluated based on the pre-test and/or diagnostic tests documented in maternity records. In 2018, the majority of all women who gave birth in hospitals had had a pre-test conducted (65.0%) or a pre-test and diagnostic test (18.2%) in line with the two-step procedure. A further 6.7% received a diagnostic test alone. GDM screening participation increased over time from 83.4% in 2016 to 89.9% in 2018. The prevalence of a documented GDM increased from 4.6% to 6.8% between 2013 and 2018. In 2018, this equates to 51,318 women with GDM. Reliably assessing the extent and causes of this development will require continuous analyses of screening implementation, documentation and changes in maternal risk factors. |
format | Online Article Text |
id | pubmed-8734204 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Robert Koch Institute |
record_format | MEDLINE/PubMed |
spelling | pubmed-87342042022-02-09 Gestational diabetes in Germany: Development of screening participation and prevalence Reitzle, Lukas Schmidt, Christian Heidemann, Christin Icks, Andrea Kaltheuner, Matthias Ziese, Thomas Scheidt-Nave, Christa J Health Monit Focus Gestational diabetes mellitus (GDM) is an important risk factor for pregnancy complications. Since 2012, the Federal Joint Committee’s maternity directive recommends a two-step screening for GDM with a pre-test and subsequent diagnostic test if the pre-test is positive. This study analyses the implementation and development over time of GDM screening participation and prevalence in Germany. The data basis is the external inpatient obstetrics quality assurance documentation, which covers all births in hospital. Women with diabetes before pregnancy were excluded. The study defined women as GDM cases if the condition was documented in maternity records or if the ICD-10 diagnosis O24.4 was coded for inpatients at discharge and figures were determined for the years 2013 to 2018. As the documentation of screening tests has only been included in the data set since 2016, screening participation for the years 2016 to 2018 were estimated and evaluated based on the pre-test and/or diagnostic tests documented in maternity records. In 2018, the majority of all women who gave birth in hospitals had had a pre-test conducted (65.0%) or a pre-test and diagnostic test (18.2%) in line with the two-step procedure. A further 6.7% received a diagnostic test alone. GDM screening participation increased over time from 83.4% in 2016 to 89.9% in 2018. The prevalence of a documented GDM increased from 4.6% to 6.8% between 2013 and 2018. In 2018, this equates to 51,318 women with GDM. Reliably assessing the extent and causes of this development will require continuous analyses of screening implementation, documentation and changes in maternal risk factors. Robert Koch Institute 2021-06-16 /pmc/articles/PMC8734204/ /pubmed/35146306 http://dx.doi.org/10.25646/8325 Text en © Robert Koch Institute. All rights reserved unless explicitly granted. https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License. |
spellingShingle | Focus Reitzle, Lukas Schmidt, Christian Heidemann, Christin Icks, Andrea Kaltheuner, Matthias Ziese, Thomas Scheidt-Nave, Christa Gestational diabetes in Germany: Development of screening participation and prevalence |
title | Gestational diabetes in Germany: Development of screening participation and prevalence |
title_full | Gestational diabetes in Germany: Development of screening participation and prevalence |
title_fullStr | Gestational diabetes in Germany: Development of screening participation and prevalence |
title_full_unstemmed | Gestational diabetes in Germany: Development of screening participation and prevalence |
title_short | Gestational diabetes in Germany: Development of screening participation and prevalence |
title_sort | gestational diabetes in germany: development of screening participation and prevalence |
topic | Focus |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734204/ https://www.ncbi.nlm.nih.gov/pubmed/35146306 http://dx.doi.org/10.25646/8325 |
work_keys_str_mv | AT reitzlelukas gestationaldiabetesingermanydevelopmentofscreeningparticipationandprevalence AT schmidtchristian gestationaldiabetesingermanydevelopmentofscreeningparticipationandprevalence AT heidemannchristin gestationaldiabetesingermanydevelopmentofscreeningparticipationandprevalence AT icksandrea gestationaldiabetesingermanydevelopmentofscreeningparticipationandprevalence AT kaltheunermatthias gestationaldiabetesingermanydevelopmentofscreeningparticipationandprevalence AT ziesethomas gestationaldiabetesingermanydevelopmentofscreeningparticipationandprevalence AT scheidtnavechrista gestationaldiabetesingermanydevelopmentofscreeningparticipationandprevalence |